Agree $7-$8 short term, $10+ by Q1 2017 IMO. Just need the losing shorts to go thru their covering manipulation madness & ARLZ will head into clear skies. Shorties finding out that it's a Bad Idea to bet against CEO Adrian Adams.
Yosprala USA /Zontivity sales starting in Oct 2016
Filing for approval of Yosprala in the EU & Canada on deck, filing in Q4 2016 for approval of Treximet/MT 400 in Canada
Just like his previous companies, CEO Adams is positioning ARLZ to be sold at a healthy premium. Patience, let it play out IMO.
News 
Market Data 
Discover 
